H.R. 2387 prohibits the use of federal funds in connection with medical or surgical services the bill calls “sex‑trait altering treatment” when furnished to minors. It also conditions federal program eligibility, bars federal regulatory or subregulatory promotion of such treatments, and forbids federal funding to institutions that provide them to people under 18.
Beyond funding controls, the bill creates multiple private enforcement paths: taxpayers and private individuals can sue to enjoin or recover for agency or federal funding violations; individuals harmed by treatments performed as minors can bring malpractice and civil actions with extended limitations periods and enhanced damages; and health‑care personnel receive statutory conscience protections. Those combined features make program administrators, providers, hospitals, schools, insurers, and States the primary targets of the bill’s levers.
At a Glance
What It Does
The bill defines a broad category of “sex‑trait altering treatment” and denies federal funds for paying, sponsoring, promoting, assisting, or supporting those services for minors; it also prohibits federal agencies from taking regulatory or subregulatory actions that promote them. The text attaches funding conditions to specific federal programs, prohibits federal support for institutions that provide such treatments to minors, and creates private rights of action and medical‑liability remedies for affected individuals.
Who It Affects
Medicaid programs and other HHS‑administered funding streams, hospitals, clinics, medical schools, federally qualified health centers, elementary and secondary schools receiving federal funds, providers who prescribe or perform gender‑related care, insurers, and States that participate in federal programs. Parents and minors are affected through consent and private‑suit provisions.
Why It Matters
The bill uses federal spending and program‑eligibility conditions plus private litigation to regulate medical practice for minors, rather than establishing a medical standard in a licensing framework. That combination can shift where disputes play out (federal courts and funding determinations) and raise compliance, liability, and program‑administration risks for public and private health actors.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill begins by singling out a defined set of medical and surgical services it calls “sex‑trait altering treatment” and places those services outside the reach of federal funding when provided to anyone under 18. The statutory definition is detailed: it covers puberty blockers, gender‑transition hormones when dosed above endogenous levels, genital and nongenital reassignment surgeries, and other procedures the text lists.
The measure also carves out narrowly described exceptions—chiefly for medically verifiable disorders of sex development (DSD), acute life‑threatening conditions, and treatment of complications caused by prior sex‑trait altering interventions.
To enforce the funding restrictions, the bill operates on three tracks. First, it denies federal dollars for direct payment or support of the listed treatments and conditions program eligibility for states—naming Medicaid (Title XIX) and IV‑A as examples for some provisions—and further forbids federal agencies from taking regulatory steps that would “promote” these services to minors.
Second, it disqualifies medical institutions from receiving federal funds if they provide the banned services to minors. Third, it supplements administrative enforcement with private litigation: taxpayers and other private parties may sue agencies or the United States for violations of federal‑funding bans, and parents or harmed individuals can bring civil suits against providers and states.The bill builds parental‑consent and provider‑conscience protections into the scheme.
It requires parental informed consent procedures for minors receiving services (including a consultation and a written consent requirement tied to a minimum waiting period before treatment), bars federal funding to any state that implements policies delivering sex‑trait altering care to a minor without parental consent or that separates a child from a parent solely for refusal to consent, and creates statutory conscience rights for an expansive list of health‑care actors. For providers, the measure also creates a private malpractice and civil liability path for individuals harmed by treatments performed during minority, including an unusually long statute of limitations and enhanced damages remedies.Education settings are addressed separately: elementary and secondary schools that allow school personnel to provide or facilitate such treatments without notifying parents and receiving written parental approval would lose federal funding.
Finally, the bill adjusts the federal criminal statute on female genital mutilation by specifying that procedures done for the purpose of “change of gender or sex” or “affirmation of gender or sex” do not fall within health‑necessity exceptions—potentially broadening criminal liability in certain contexts.
The Five Things You Need to Know
The bill’s private enforcement regime lets any person—including a taxpayer—sue federal agencies or the United States for violating the federal‑funding bans, not only affected providers or patients.
Section 7 imposes a pre‑treatment informed‑consent regime requiring a parent consultation, a printed list of risks, and written parental consent obtained at least 72 hours before furnishing treatment to a minor.
Section 8 creates a malpractice/civil‑liability cause of action for individuals harmed by sex‑trait altering treatment performed as minors, awards attorney’s fees and litigation costs, and authorizes treble damages.
The statute of limitations for parental or injured‑party suits tied to parental‑consent, informed‑consent, and malpractice provisions allows actions up to 30 years after the plaintiff reaches majority.
Section 4 amends the federal FGM statute to state that ‘‘necessary to the health of the person’’ does not include change or affirmation of gender or sex, narrowing a health exception that could affect prosecutorial decisions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Ban on federal funds for sex‑trait altering treatments for minors
This section frames the core funding prohibition: no federal funds may be used to pay for, sponsor, promote, assist, or otherwise support the furnishing of defined sex‑trait altering treatments to anyone under age 18. Practically, that language sweeps across grant programs, direct payments, and federal contracts—whenever federal money touches the delivery chain. Because the bar applies to funds used for sponsoring or promoting services as well as paying for them, agencies responsible for grants, technical assistance, or educational materials could be implicated if their activities relate to the proscribed services.
Ban on federal regulatory or subregulatory promotion
This section prevents federal agencies from using funds to take regulatory or informal regulatory (subregulatory) actions that would promote sex‑trait altering treatments to minors. That creates potential constraints on agency guidance, communications, model policies, and rulemaking that agencies might otherwise use to standardize care or provide clinical guidance. The text pairs the ban with a private right of action, making agency guidance a likely litigation target if plaintiffs say it amounts to promotion.
FGM statute amendment — limits ‘health’ exception
By amending 18 U.S.C. 116, the bill clarifies that for purposes of FGM prosecutions the phrase “necessary to the health of the person” does not cover gender change or affirmation. The effect is to narrow a statutory safety valve that defense counsel or prosecutors sometimes litigate in cases involving culturally or medically contested genital procedures. This change potentially brings some gender‑related surgeries closer to criminal scrutiny if other elements of the FGM statute apply.
Denial of federal funds to institutions that provide treatments to minors
The bill targets institutions—hospitals, clinics, medical schools, FQHCs, rural health centers, and medical practices—that provide sex‑trait altering treatments to minors by forbidding federal funds to such institutions. That means entities that perform the listed services face the choice of continuing those services but giving up federal reimbursements, grants, hosting agreements for trainees, or other federal support, or discontinuing the services to retain federal funding streams.
Parental‑consent protections and conditions on state funding
This section gives parents an explicit statutory right to decline treatment for their minor, and it conditions certain federal funds (specifically Medicaid Title XIX and IV‑A in the text) on states not having policies that provide these treatments without parental consent or that remove minors from parents solely for parental refusal. The provision opens a litigation path for injured minors or parents against States and the United States and establishes long‑running statute‑of‑limitations protections for plaintiffs.
Informed‑consent procedural requirements for providers
Section 7 requires health‑care providers to hold a consultation with parents, give a printed list of potential side effects including permanent fertility or sexual‑function risks, and secure written informed parental consent at least 72 hours before furnishing any covered treatment to a minor. Failure to follow those steps creates a private cause of action for the minor or parent; the combination of procedural prerequisites and civil liability elevates the administrative burden on clinicians and systems that treat adolescents.
Medical malpractice and damages regime
This section creates a standalone civil action for physical, psychological, or physiological harms caused by sex‑trait altering treatments performed on minors. Successful plaintiffs recover attorney’s fees, litigation costs, and treble damages. The provision also sets an extended statute of limitations tied to attainment of majority, which increases the long‑tail exposure of providers, hospitals, and insurers for care delivered to minors.
Conscience protections for health‑care providers and broad definition of provider
The bill bars penalties or discrimination against providers who decline to perform, refer, pay for, cover, or arrange sex‑trait altering treatments. It conditions HHS program funding on states not requiring providers to deliver such services, and defines “health care provider” extremely broadly—individual clinicians, hospitals, insurers, training programs, organizations (including entities resulting from mergers), and even applicants to training programs—so many actors gain statutory conscience protections. That breadth means employers, insurers, and educational programs may invoke the statute in personnel or credentialing disputes.
Restrictions on federal funds to schools for treatments without parental consent
This section denies federal funds to elementary and secondary schools that allow school personnel to provide or support sex‑trait altering treatments to students without notifying parents and obtaining written parental approval. By tying the restriction to common ESEA definitions of school personnel and programs, the provision reaches a wide set of K–12 contexts and means school districts must redesign policies on parental notification and student health services to preserve federal education dollars.
Definitions and exceptions
The definitions section is lengthy and programmatic: it enumerates what counts as sex‑trait altering treatments (puberty blockers, gender hormones at supra‑endogenous doses, genital and nongenital surgeries), defines sex and gender, lists specific surgical procedures captured, and identifies exceptions (medically verifiable DSD conditions, life‑threatening circumstances, treatments of complications of prior procedures, and non‑treatment mental‑health services). Those definitions will be central in litigation over whether a particular service or clinical pathway falls inside the ban.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Parents opposed to minors receiving gender‑affirming medical or surgical interventions — the bill strengthens parental consent rights and creates multiple legal avenues to block or reverse state or institutional policies that provide such care without parental approval.
- Health‑care providers and organizations with conscience objections — the statute grants broad protections against penalty or discrimination for declining to participate, and conditions HHS funding against state mandates that would force participation.
- Advocates for tighter federal oversight of youth gender‑transition treatments — the bill centralizes federal leverage to limit access through funding and creates private enforcement mechanisms that supporters can use to compel compliance.
Who Bears the Cost
- Hospitals, clinics, medical schools, FQHCs, and rural health centers that currently provide gender‑affirming care to minors — they risk losing federal reimbursements, grants, training dollars, and research funding if they maintain such services.
- State Medicaid programs and social‑service agencies — the statute conditions Title XIX and IV‑A funds on state policies and could force changes to eligibility, custody, or consent practices to avoid funding cuts, creating administrative disruption and litigation risk.
- Providers, professional societies, and insurers — clinicians face new procedural steps, long‑tail malpractice exposure (treble damages and 30‑year filing windows), and potential conflicts with prevailing medical‑standard guidance; insurers may see higher litigation and indemnity costs.
Key Issues
The Core Tension
The bill pits the federal government’s willingness to use spending power and private litigation to restrict access to gender‑related medical care for minors against clinical autonomy, established medical standards, and access to care: it aims to prevent what supporters view as harmful, irreversible interventions on minors, but it does so by reshaping funding incentives and creating litigation and liability pressure that may deny or delay medically indicated care, stoke regulatory uncertainty, and displace medical decision‑making into courts and funding offices.
The bill’s enforcement architecture relies heavily on federal spending conditions plus private litigation. That design raises two related implementation challenges.
First, federal agencies and program administrators will need to define what constitutes ‘‘use’’ or ‘‘promotion’’ of federal funds in contexts such as research grants, medical education, telehealth technical assistance, or agency guidance—areas where the line between permissible activity and prohibited promotion is often fact‑specific. Second, the private right of action for any person (including taxpayers) invites preenforcement and programmatic litigation over agency materials, grant awards, or state plan language, potentially clogging federal courts and creating inconsistent judicial interpretations that then govern program administration.
The bill also creates practical medical conflicts. Its detailed definitions and narrow exceptions turn clinical judgments about DSD, puberty suppression for diagnostic purposes, and treating complications into legal questions.
Providers may decline care to avoid liability even in close cases, producing a chilling effect that could reduce access to legitimate medical and mental‑health services for minors. Treble damages and a three‑decade statute of limitations create significant insurer and provider exposure, which could raise malpractice premiums or lead institutions to restructure pediatric services.
Finally, the conscience provisions are unusually broad—covering organizations, trainees, and applicants—so institutions may face conflicts between nondiscrimination obligations and statutory conscience claims that a future court must reconcile.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.